1,4-Bis[(p-hydroxyphenethyl)amino]-anthraquinone Property

Boiling point:

780.2±60.0 °C(Predicted)

Density 

1.370±0.06 g/cm3(Predicted)

storage temp. 

Room temp

solubility 

DMSO: ≥10mg/mL

pka

9.76±0.15(Predicted)

form 

solid

color 

violet

Safety

Hazard Codes 

N

Risk Statements 

50/53

Safety Statements 

60-61

RIDADR 

UN 3077 9/PG 3

WGK Germany 

3

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H400Very toxic to aquatic life

Precautionary statements

P273Avoid release to the environment.

1,4-Bis[(p-hydroxyphenethyl)amino]-anthraquinone Chemical Properties,Usage,Production

Description

Human sirtuin 2 (SIRT2) is a NAD⁺-dependent protein deacetylase with diverse targets, including α-tubulin, phosphoenolpyruvate carboxykinase, and forkhead box protein O1. JFD00244 is an inhibitor of SIRT2 (IC₅₀= 56.7 μM). At 5 μM, JFD00244 induces granulocytic differentiation in the acute promyelocytic leukemia cell line NB4.

Uses

BML-266 is an inhibitor of SIRT2.

Definition

ChEBI: 1,4-bis[2-(4-hydroxyphenyl)ethylamino]anthracene-9,10-dione is an anthraquinone.

in vitro

in a previou study, the molecular modeling and virtual screening were utilized to identify potential compounds, which were then subjected to experimental tests for their sirt2 inhibitory activity. five of the 15 tested compounds including jfd00244 displayed inhibitory activity toward sirt2, resulting in a hit ratio of 33% in a micromolar level. jfd00244 and another analog of the five compounds yielded in vitro ic(50) values of 56.7 and 74.3 microm, respectively. on the basis of these results, a phenol moiety on the active compounds including jfd00244 was suggested to be critical for sirt2 inhibitory activity. this phenol group, together with a hydrophobic moiety and hydrogen-bonding features, was thus recommended to form an active sirt2 pharmacophore [1].

IC 50

56.7 μm

References

[1] tervo aj, kyrylenko s, niskanen p, salminen a, leppnen j, nyrnen th, jrvinen t, poso a. an in silico approach to discovering novel inhibitors of human sirtuin type 2. j med chem. 2004 dec 2;47(25):6292-8.